buy earn in-lin compani
execut kra develop program
messag report earn larg line
expect compani continu execut kra inhibitor
phase updat well pivot phase ii monotherapi
multipl combin studi keytruda erbitux underway
addit combin studi inhibitor novn egfr inhibitor
gilotrif boehring ingelheim inhibitor ibranc track initi
preclin data inhibitor expect year well updat
estim account increas opex maintain buy pt
compani initi enrol pivot phase singl agent trial non-smal
cell lung cancer nsclc highlight favor fda interact point
potenti registr pathway potenti singl trial orr
durat data although recent mention complet enrol pivot
singl arm trial competitor cite keep pace start
clinic trial month shortag patient avail compani
also reiter plan updat phase data patient
longer durat follow-up
combin trial inhibitor keytruda nsclc
erbitux colorect cancer underway management believ
subgroup analysi kra nsclc patient may repres competit
benchmark time see oncolog day oncolog panel takeaway
though caveat dataset rel small ultim believ
regimen need random confirmatori nsclc trial potenti approv
regard erbitux combin management believ clinic develop pathway
erbitux braftovi/mektovi braf serv good analog provid
posit read-through success probabl erbitux
track initi combin studi inhibitor see prior note
egfr inhibitor gilotrif inhibitor ibranc regard differ
clinical-stag inhibitor believ variou inhibitor similar molecular
profil partner novn given addit dose data
time fulli own in-hous thu simpler partner asset split
multipl parti
highlight encourag potenc select inhibitor
present preclin data year recal repres potenti attract
opportun kra mutant-select inhibitor higher overal preval
believ nsclc pancreat cancer harbor
kra mutat larg line estim
updat estim account result maintain buy pt
increas near-term expens forecast given expect initi multipl
combin trial account capit rais net
proce compani expect cash runway go maintain buy rate
pt
page analyst certif import disclosur
valuat risk
valu mirati use dcf-base valuat methodolog valuat
base probability-adjust sitravatinib opportun second-lin nsclc potenti
indic sitravatinib along probability-adjust opportun kra
cancer pipelin agent repres potenti upsid valuat use discount
rate consist development-stag biotech compani coverag
termin growth rate appli third year post assum gener
risk valuat includ regulatori commerci setback
potenti emerg new competitor dilut financ beyond assum
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc sec file
page analyst certif import disclosur
